plication No.09 821 463
-------------------------

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comfor such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):	ply with the requirements
to the following reason(s).	
1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Addressed to these regulations, published at 1114 OC 30 May 15, 1000 - 1, 1	Applicant's attack
directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230,	May 1, 1990.
r <del>'</del> N	
<ol> <li>This application does not contain, as a separate part of the disclosure on paper copy, a required by 37 CFR 1.821(c).</li> </ol>	'Sequence Listing" as
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as re	equired by 37 CED 4 co.
	oquired by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. Howev	
computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.82 attached marked-up copy of the "Raw Sequence Listing."	er, the content of the 23, as indicated on the
5. The computer readable form that has been filed with this application has been found to be unreadable as indicated on the attached CRF Diskette Problem Report. A substitute compute submitted as required by 37 CFR 1.825(d).	damaged and/or er readable form must be
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form as required by 37 CFR 1.821(e).	of the "Sequence Listing"
7. Other: ————	
7. Other:	
Applicant must provide:	
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"	
Applicant must provide:	its entry into the
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"  An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing specification  A statement that the content of the paper and computer readable copies are the sequence.	
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"  An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing specification  A statement that the content of the paper and computer readable copies are the same and, whe new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)	re applicable, include no
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"  An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing specification  A statement that the content of the paper and computer readable copies are the same and, whe new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)	re applicable, include no
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"  An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing specification  A statement that the content of the paper and computer readable copies are the same and, when new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)  or questions regarding compliance with these requirements, please contact:	re applicable, include no
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"  An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing specification  A statement that the content of the paper and computer readable copies are the same and, when new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)  or questions regarding compliance with these requirements, please contact:  The Rules Interpretation, call (703) 308-1123	re applicable, include no

Please return a copy of this notice with your response.

Please Note: As of 3/18/02

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

- Electronically submitted through EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>, EFS Submission User Manual - ePAVE)
- 2. Mailed to: U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202
- 3. Mailed by Federal Express, United Parcel Service or other delivery service to:
  U. S. Patent and Trademark Office
  2011 South Clark Place
  Customer Window, Box Sequence
  Crystal Plaza Two, Lobby, Room 1B03
  Arlington, Virginia 22202
- 4. Hand Carried directly to the Customer Window at: 2011 South Clark Place
  Crystal Plaza Two, Lobby, Room 1B03, Box Sequence, Arlington, Virginia 22202